NORML

APRIL 30, 2020

.” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5

Chronic Pain 346

Chronic Pain Clinical Trials Data Patients 346

NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. Misleading claims represent both a threat to public health and a violation of consumer access to accurate information.”

CBD 299

CBD Clinical Trials Data Treatment 299

Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The primary endpoint of our Phase 1 clinical trial was to test and demonstrate safety and tolerability.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.). “A

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). Twenty percent of those surveyed acknowledged having previously used cannabis for medical purposes.

Clinical Trials 192

Clinical Trials Chronic Pain Data Treatment 192

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

CannaMD

JUNE 2, 2021

However, little is known about these patients’ thoughts and experiences related to cannabis, or its perceived effect on the disease’s symptoms. Of those states that had legalized medical marijuana, 14 currently consider Parkinson’s disease a qualifying condition for medical marijuana therapies. Florida is among these states.

Patients 105

Patients Clinical Trials Treatment Research and Development 105

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. This will offer professionals worldwide a chance to gain insight into this research, equipping them with valuable information they can apply in their own contexts.

Clinical Trials 91

Clinical Trials Research and Development Data Collective 91

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Canna Care Docs

OCTOBER 3, 2023

As a devastating diagnosis, patients with a terminal illness must not only learn to cope with this information about their health but find restorative ways to alleviate the most common symptoms and effects. However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Veriheal

AUGUST 28, 2023

And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. Current approaches to treat this condition are helpful but do not always provide full relief. Do not attempt to self-diagnose or prescribe treatment based on the information provided.

Treatment 56

Treatment Clinical Trials Therapy Research and Development 56

The Cannigma

MARCH 18, 2021

The majority of people with Parkinson’s disease in the United States have not used cannabis to treat their symptoms due to a lack of scientific evidence about its effectiveness. Of those who have used cannabis, most did not receive a recommendation from a doctor or instructions on how to use it, according to the findings of a recent study.

Patients 138

Patients Clinical Trials Treatment Cannabis 138

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.” ” About PsyBio Therapeutics Corp.

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Veriheal

MAY 3, 2022

Cannabis use disorder (CUD) is often confused with frequent cannabis use , but CUD is significantly more worrisome. The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The researchers’ analysis found anxiety was the reason given for 16% of medicinal cannabis prescriptions. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

The Cannigma

OCTOBER 14, 2022

Recreational cannabis is not legal, despite a 2019 citizen’s initiative that called for legalization. In 2019 the Parliament approved a citizen’s proposal to regulate recreational use of cannabis, but backtracked in March 2020 , saying they would wait to follow the lead of Italy. Can you bring or buy cannabis products?

Law 56

Law Clinical Trials Research and Development Recreational 56

PrestoDoctor

SEPTEMBER 15, 2023

Obsessive-Compulsive Disorder (OCD) is a debilitating mental health condition that is characterized by intrusive thoughts and compulsive behaviors. However, recent research suggests that cannabis may be a promising option for those seeking relief from OCD symptoms. This is where cannabis comes into the picture.

Research and Development 105

Research and Development Therapy Treatment Strains 105

Cannabis Law Report

AUGUST 5, 2021

Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. Although the overarching market is still relatively new, much like the cannabis boom a few years ago the psychedelics space is growing at an unprecedented rate.

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

JANUARY 12, 2022

OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. 14, 2021, the sale of Gb Sciences’ Las Vegas cannabis facility was finalized on Dec. LAS VEGAS, Jan.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. The development has been welcomed and comes as the nation’s doctors are said to be shifting their cultural stance from viewing ‘cannabis as a dirty word’.

Data 52

Data Patients Clinical Trials Business 52

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

AUGUST 3, 2021

There are numerous risks and uncertainties that could cause actual results and Cybin’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. People want to trust their doctors, but doctors need knowledge. We have a ways to go,” Tan said.

Education 101

Education Clinical Trials Medicine Policy 101

Cannabis Law Report

SEPTEMBER 9, 2021

MYMD-1 is also being developed as a potential therapy for COVID-19-related conditions such as post-COVID-19 syndromes. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain. 646) 421-9523.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene. Conference Call and Webcast Details.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Veriheal

JULY 16, 2020

The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. The Commission Focused on Veteran Well-being. Veterans across the U.S.

Research and Development 81

Research and Development Clinical Trials Treatment Compliance 81

Veriheal

MAY 12, 2021

The relationship between cannabis and cancer has long been at the forefront of research regarding its medical efficacy, mainly for legalization and treatment purposes. However, cannabis use amongst those with cancer is poorly understood, at least according to a team of researchers.

Patients 98

Patients Consumption Clinical Trials Education 98

Cannabis Law Report

AUGUST 25, 2021

Acquisition Advances Company’s Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis. Kotra taking on the role of leading the development of FSD Pharma’s drug development pipeline in Psychedelics and Medical Cannabis.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

JUNE 30, 2021

Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

The Cannigma

MARCH 7, 2022

Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . Of course, this plant is now known to be marijuana (or Type I cannabis), which is still commonly used for sleep and analgesia today. The best online schools for medical cannabis training.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In part of one of this series, we analyzed the discussions surrounding using cannabis for mental health. In part two, we took a deep look at using cannabis for depression. In part three, we will analyze the available research concerning cannabis and anxiety. Can you use cannabis for anxiety? Cannabis and Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

JANUARY 10, 2022

In addition, rising strategic initiatives by key players in the form of collaborations, clinical trials, and production are further contributing to increasing awareness and adoption of THCV products. Rising clinical trials is thus anticipated to boost the adoption and penetration of rare cannabis derivatives in the forthcoming years.

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52